Bolt Biotherapeutics, Inc. (BOLT) shareholders
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/3030% below fair value
$6.08+0.17 (+2.88%)
Close on Nov 13, 2026Market cap $11.71MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
31.0%
1M of 2M shares
Institutional holders
23
2 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
5 buys · 9 sales
Net bought $196.24K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vivo Capital VIII, LLC | 2,073,005 | 5.50% | 13G (passive) amendment | Dec 31, 2023 |
| Matthew D. Perry Joint filing with Coastlands Capital LP (17.50%), Coastlands Capital Partners LP (17.50%) and 2 more | 412,416 | 17.50% | 13G (passive) | Oct 30, 2026 |
| Renaissance Technologies Holdings Corporation Joint filing with Renaissance Technologies LLC (5.13%) | 98,625 | 5.13% | 13G (passive) | Jun 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BOLT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 137,721 | 7.15% | $530.23K | – | 0.03% |
| Renaissance Technologies LLC | 98,625 | 5.12% | $379.71K | +21,400 | 0.00% |
| Vivo Capital, LLC | 72,414 | 3.76% | $278.79K | – | 0.03% |
| Citadel Advisors LLC | 56,903 | 2.95% | $219.08K | +46,794 | 0.00% |
| T3 Companies, LLC | 38,000 | 1.97% | $146.30K | – | 0.16% |
| Board of Trustees of The Leland Stanford Junior University | 35,977 | 1.87% | $138.51K | – | 0.03% |
| Pfizer Inc | 31,305 | 1.63% | $133.83K | – | 0.08% |
| Lynx1 Capital Management LP | 30,800 | 1.60% | $118.58K | – | 0.01% |
| Nano Cap New Millennium Growth Fund L P | 27,500 | 1.43% | $105.88K | – | 0.08% |
| Geode Capital Management, LLC | 19,119 | 0.99% | $73.62K | −9,672 | 0.00% |
| Shay Capital LLC | 15,438 | 0.80% | $59.44K | +533 | 0.00% |
| BlackRock, Inc. | 9,711 | 0.50% | $37.39K | – | 0.00% |
| Vanguard Capital Management LLC | 7,060 | 0.37% | $27.18K | – | 0.00% |
| Nan Fung Group Holdings Ltd | 5,000 | 0.26% | $19.25K | −24,250 | 0.01% |
| Morgan Stanley | 3,145 | 0.16% | $12.11K | −44 | 0.00% |
| Vanguard Fiduciary Trust Co | 3,095 | 0.16% | $11.92K | – | 0.00% |
| NewEdge Advisors, LLC | 2,530 | 0.13% | $9.74K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 1,710 | 0.09% | $6.58K | +617 | 0.00% |
| UBS Group AG | 255 | 0.01% | $982 | −532 | 0.00% |
| SBI Securities Co., Ltd. | 130 | 0.01% | $501 | +120 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 1M | 31.0% | 2 / 5 | 4 / 3 | 0M | 0M |
| Q1 2026 | 24 | 1M | 31.8% | 6 / 6 | 3 / 2 | 0M | 0M |
| Q4 2025 | 21 | 1M | 31.3% | 3 / 4 | 5 / 6 | 0M | 0M |
| Q3 2025 | 24 | 1M | 41.7% | 3 / 3 | 8 / 4 | 0M | 0M |
| Q2 2025 | 25 | 1M | 46.1% | 25 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held BOLT in Q2 2026, 22% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BOLT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 17,060 | 0.89% | $89.57K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 7,060 | 0.37% | $27.18K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 5,348 | 0.28% | $28.08K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 1,699 | 0.09% | $8.92K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 143 | 0.01% | $751 | 0.00% | May 31, 2026 |
| Diversified Equity Alpha Master Portfolio | 89 | 0.00% | $343 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sheila Gujrathi | Chief Strategy Officer, Director | 85,821 | 4.46% | Oct 27, 2026 |
| William P. Quinn | President, CEO and CFO, Director | 25,384 | 1.32% | Sep 21, 2026 |
| Grant Yonehiro | Chief Operating Officer | 17,269 | 0.90% | Sep 21, 2026 |
| Sarah Nemec | Senior VP, Finance and PAO | 17,082 | 0.89% | Sep 21, 2026 |
| Nicole Onetto | Director | 0 | – | Jun 11, 2026 |
| Laura Berner | Director | 0 | – | Jun 11, 2026 |
| Kathleen Laporte | Director | 1,200 | 0.06% | Jun 11, 2026 |
| Jakob Dupont | Director | – | – | Jun 11, 2026 |
| Brian O'Callaghan | Director | 0 | – | Jun 11, 2026 |
| Capital LP Coastlands | 10% owner | 462,416 | 24.00% | Nov 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Capital LP Coastlands 10% owner | Nov 9, 2026 | Buy | +50,000 | $6.38 | $319.00K | 462,416 |
| Sheila Gujrathi Chief Strategy Officer, Director | Oct 23, 2026 | Award | +13,055 | – | – | 13,055 |
| Sheila Gujrathi Chief Strategy Officer, Director | Oct 23, 2026 | Award | +72,766 | – | – | 72,766 |
| Sarah Nemec Senior VP, Finance and PAO | Sep 18, 2026 | Sale | −4,077 | $3.24 | $13.21K | 17,082 |
| Grant Yonehiro Chief Operating Officer | Sep 18, 2026 | Sale | −6,850 | $3.24 | $22.19K | 17,269 |
| William P. Quinn President, CEO and CFO, Director | Sep 18, 2026 | Sale | −9,132 | $3.24 | $29.59K | 25,384 |
| Sarah Nemec Senior VP, Finance and PAO | Sep 17, 2026 | Sale | −2,922 | $3.32 | $9.70K | 21,159 |
| Grant Yonehiro Chief Operating Officer | Sep 17, 2026 | Sale | −4,909 | $3.32 | $16.30K | 24,119 |
| William P. Quinn President, CEO and CFO, Director | Sep 17, 2026 | Sale | −6,545 | $3.32 | $21.73K | 34,516 |
| Sarah Nemec Senior VP, Finance and PAO | Sep 16, 2026 | Sale | −843 | $3.77 | $3.18K | 24,081 |
| Grant Yonehiro Chief Operating Officer | Sep 16, 2026 | Sale | −1,417 | $3.77 | $5.34K | 29,028 |
| William P. Quinn President, CEO and CFO, Director | Sep 16, 2026 | Sale | −1,889 | $3.77 | $7.12K | 41,061 |
| Sarah Nemec Senior VP, Finance and PAO | Jun 5, 2026 | Buy | +509 | $3.88 | $1.97K | 1,924 |
| William P. Quinn President, CEO and CFO, Director | Jun 5, 2026 | Buy | +637 | $3.88 | $2.47K | 2,950 |
| Sarah Nemec Senior VP, Finance and PAO | Dec 5, 2025 | Buy | +125 | $4.61 | $576 | 1,415 |
| William P. Quinn President, CEO and CFO, Director | Dec 5, 2025 | Buy | +125 | $4.61 | $576 | 2,313 |
| William P. Quinn President, CEO and CFO, Director | Oct 22, 2025 | Award | +40,000 | – | – | 42,188 |
| Sarah Nemec Senior VP, Finance and PAO | Oct 22, 2025 | Award | +23,000 | – | – | 23,943 |
| Grant Yonehiro Chief Operating Officer | Oct 22, 2025 | Award | +30,000 | – | – | 38,918 |
| William P. Quinn President, CEO and CFO, Director | Jun 6, 2025 | Buy | +125 | $5.49 | $686 | 2,188 |
| Sarah Nemec Senior VP, Finance and PAO | Jun 6, 2025 | Buy | +125 | $5.49 | $686 | 943 |
| Sarah Nemec Senior VP, Finance and PAO | Dec 16, 2024 | Buy | +2,500 | $0.50 | $1.25K | 16,633 |
| William P. Quinn President, CEO and CFO, Director | Dec 16, 2024 | Buy | +2,500 | $0.50 | $1.25K | 41,272 |
| Sarah Nemec Senior VP, Finance and PAO | Jun 6, 2024 | Buy | +2,500 | $0.64 | $1.60K | 13,863 |
| William P. Quinn President, CEO and CFO, Director | Jun 6, 2024 | Buy | +2,500 | $0.64 | $1.60K | 38,772 |
| William P. Quinn Chief Financial Officer | Dec 12, 2023 | Buy | +7,500 | $0.95 | $7.13K | 36,272 |
| Edith A. Perez Chief Medical Officer | Dec 6, 2023 | Buy | +2,500 | $0.78 | $1.95K | 46,612 |
| Randall C. Schatzman Chief Executive Officer, Director | Dec 6, 2023 | Buy | +2,500 | $0.78 | $1.95K | 12,859 |
| Grant Yonehiro Chief Business Officer | Dec 6, 2023 | Buy | +2,500 | $0.78 | $1.95K | 8,918 |
| William P. Quinn Chief Financial Officer | Dec 6, 2023 | Buy | +2,500 | $0.78 | $1.95K | 28,772 |
| Edgar Engleman Director | Nov 30, 2023 | Sale | −108,145 | $0.86 | $93.00K | 1,821,483 |
| Edgar Engleman Director | Nov 30, 2023 | Sale | −14,934 | $0.86 | $12.84K | 251,522 |
| Edgar Engleman Director | Nov 29, 2023 | Sale | −3,131 | $0.91 | $2.85K | 266,456 |
| Edgar Engleman Director | Nov 29, 2023 | Sale | −22,674 | $0.91 | $20.63K | 1,929,628 |
| Edgar Engleman Director | Nov 21, 2023 | Sale | −1,707 | $0.90 | $1.54K | 1,952,302 |
| Edgar Engleman Director | Nov 21, 2023 | Sale | −236 | $0.90 | $212 | 269,587 |
| Vivo Capital VIII, LLC 10% owner | Nov 21, 2023 | Sale | −1,457 | $0.90 | $1.31K | 111,662 |
| Vivo Capital VIII, LLC 10% owner | Nov 21, 2023 | Sale | −1,707 | $0.90 | $1.54K | 1,952,302 |
| Vivo Capital VIII, LLC 10% owner | Nov 21, 2023 | Sale | −236 | $0.90 | $212 | 269,587 |
| Edgar Engleman Director | Nov 20, 2023 | Sale | −27,465 | $0.92 | $25.27K | 1,954,009 |
| Edgar Engleman Director | Nov 20, 2023 | Sale | −3,792 | $0.92 | $3.49K | 269,823 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 20, 2023 | Sale | −27,465 | $0.92 | $25.27K | 1,954,009 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 20, 2023 | Sale | −3,792 | $0.92 | $3.49K | 269,823 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 20, 2023 | Sale | −23,443 | $0.92 | $21.57K | 113,119 |
| Edgar Engleman Director | Nov 17, 2023 | Sale | −8,211 | $0.93 | $7.64K | 1,981,474 |
| Edgar Engleman Director | Nov 17, 2023 | Sale | −1,134 | $0.93 | $1.05K | 273,615 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 17, 2023 | Sale | −8,211 | $0.93 | $7.64K | 1,981,474 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 17, 2023 | Sale | −7,009 | $0.93 | $6.52K | 136,562 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 17, 2023 | Sale | −1,134 | $0.93 | $1.05K | 273,615 |
| Edgar Engleman Director | Nov 16, 2023 | Sale | −7,531 | $0.96 | $7.23K | 1,989,685 |
| Edgar Engleman Director | Nov 16, 2023 | Sale | −1,040 | $0.96 | $998 | 274,749 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 16, 2023 | Sale | −6,429 | $0.96 | $6.17K | 143,571 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 16, 2023 | Sale | −1,040 | $0.96 | $998 | 274,749 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Nov 16, 2023 | Sale | −7,531 | $0.96 | $7.23K | 1,989,685 |
| Edith A. Perez Chief Medical Officer | Jun 6, 2023 | Buy | +2,070 | $1.18 | $2.44K | 44,112 |
| Randall C. Schatzman Chief Executive Officer, Director | Jun 6, 2023 | Buy | +2,500 | $1.18 | $2.95K | 10,359 |
| William P. Quinn Chief Financial Officer | Jun 6, 2023 | Buy | +1,829 | $1.18 | $2.16K | 26,272 |
| William P. Quinn Chief Financial Officer | Dec 6, 2022 | Buy | +1,789 | $1.18 | $2.11K | 24,443 |
| Edith A. Perez Chief Medical Officer | Dec 6, 2022 | Buy | +2,500 | $1.18 | $2.95K | 42,042 |
| Grant Yonehiro Chief Business Officer | Dec 6, 2022 | Buy | +2,500 | $1.18 | $2.95K | 6,418 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.80%
0M shares short
Days to cover
1.0
At 1M shares a day
Change since last report
+200.8%
From 0M shares
Short volume, 20 days
55.3%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bolt Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,401 shares on Aug 24, 2026 over the last 90 days.
See a number that looks wrong?